NICE Recommends Sanofi and Regeneron’s Libtayo for CSCC
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for National Health Service (NHS) use in the treatment of patients with metastatic or locally advanced cutaneous squamous-cell carcubina, a relatively common form of skin cancer.
Previously, NICE recommended the use of Libtayo through the Cancer Drugs Fund in 2019. Now, with clinical trial results and real-world data, the agency felt ready to recommend the drug for routine NHS use.
At the time of NICE’s recommendation, Libtayo cost more than $5,800 per 350 mg vial — more than $101,000 dollars for one year of therapy. The negotiated price for NHS wasn’t disclosed.
As of now, NICE’s recommendation has become a positive final appraisal determination, making Libtayo the first systemic treatment option in England for this indication.
May 27, 2022